Servier is a privately-run French research-based pharmaceutical company with a significant presence in Europe and emerging markets. With particular expertise in the development of treatments for cardiovascular disease and a focus on advancing the most promising targets in specific disease areas, the company is well-aligned with miRagen’s approach to new therapeutics development. Servier supports the research and development of microRNA programs in the area of cardiovascular disease in a highly collaborative partnership.
miRagen and Servier entered into their strategic collaboration in October 2011 with the goal of advancing microRNA-based therapies for the treatment of cardiovascular disease. The Servier alliance initially included two of miRagen’s programs targeting miR-208 and miR-15/195 and granted Servier the right to add one additional target. In May 2013, Servier elected to add a third, undisclosed target and in June 2014 Servier and miRagen announced that they had extended their research collaboration by two years to October 2016.
Under the terms of the agreement, miRagen received an upfront payment in 2011, is scheduled to receive a target selection payment in 2013 and additional research and development milestones per target. miRagen is also eligible to receive commercial milestones and royalties on the sale of products under the strategic alliance. Servier will finance the research, development, regulatory approval, and commercialization costs of the three product candidates. miRagen retains all commercialization rights in the U.S. and Japan, and the option to co-sponsor any Phase III programs in the event that miRagen, alone or together with a partner, should seek marketing approvals for any of the targets in the U.S. and Japan.